Ottawa Citizen

Calls grow for tighter acetaminop­hen controls

Inuk activist’s liver failure puts spotlight on popular painkiller’s overdose risks

- ELIZABETH PAYNE

Acetaminop­hen, one of the most widely used and readily available painkiller­s in Canada, played a role in the hospitaliz­ation of Inuk activist Delilah Saunders last month with acute liver failure.

That fact surprised some of her family and friends, but it doesn’t surprise Dr. Eric Yoshida, who chairs the medical advisory committee of the Canadian Liver Foundation.

“This is something we get called about all the time,” said Yoshida, a leading liver transplant specialist in Vancouver.

He just had a call this week, in fact, about a patient suffering from acute liver failure after inadverten­tly taking too much acetaminop­hen.

Some of those patients recover with treatment, as Saunders did.

Some receive life-saving liver transplant­s, and others die.

That “carnage”, as he calls it, is both under-recognized by the public and largely unnecessar­y, a frustrated Yoshida says.

“I am really angry about this. It seems to be constant and the worst part is it is not getting better. It is young people, it is old people, it is everybody.”

What adds to the frustratio­n, says Yoshida, is that he believes Health Canada is not doing enough to limit the danger of acetaminop­hen overdoses, despite a recent safety review and new labelling requiremen­ts set to begin this year.

Acetaminop­hen is the leading cause of acute liver failure in Canada, sending about 4,500 Canadians, like Saunders, to hospital every year. The Ottawa woman, who is now recovering at her parents’ home in Labrador, had a history of alcohol abuse which was likely a factor, according to doctors, but her family was told acetaminop­hen, which she took to ease jaw pain, caused the acute liver failure.

Acetaminop­hen is found in about 350 over-the-counter products sold in Canada, including Tylenol. Although the majority of acetaminop­hen overdoses are intentiona­l, about 20 per cent are accidental and that number has risen in recent years. Acetaminop­hen is more likely to cause damage in the livers of people who abuse alcohol or have underlying liver problems.

A key to preventing unintentio­nal overdoses, Yoshida believes, would be limiting sales of acetaminop­hen to 325 mg tablets, which would mean the end of popular Extra Strength Tylenol, which contains 500 mg of acetaminop­hen.

The availabili­ty of large containers of high dosage acetaminop­hen, he said, makes it too easy for people to accidental­ly — or intentiona­lly — take too many. “It doesn’t make any sense. There is no need for 500 mg size,” he said.

Health Canada considered limiting products to a maximum of 325 mg units that but concluded there was not enough support. It also rejected reducing the maximum recommende­d daily dose from four to three grams — something done voluntaril­y by Johnson & Johnson, the manufactur­er of Tylenol, in the U.S.

Yoshida notes that people who want to intentiona­lly harm themselves can do a lot more damage quickly with a bottle of 500 mg tablets than with 325 mg tablets.

Getting rid of Extra Strength Tylenol, he said, would prevent “several hospital admissions every year in every single province.”

Gerry Harrington, vice president of policy at Consumer Health Products of Canada, which represents Johnson & Johnson and other companies that sell products with acetaminop­hen, said the drug used appropriat­ely “is extremely safe, right up to 500 mg.”

But he acknowledg­ed that acetaminop­hen overdose “is an issue,” in part because of the ubiquitous­ness of the product.

He said stronger warning labels, including warnings that people who take more than three drinks a day should not use acetaminop­hen, are the best approach. Label changes, to take effect this year, will require that all products that contain acetaminop­hen clearly say so.

One factor in some unintentio­nal overdoses is that people sometimes take multiple products containing acetaminop­hen — such as cold medication­s — without knowing it.

Sylvia Hyland, vice president and chief operating officer at the non-profit Institute for Safe Medication Practices Canada, called labelling changes “a step in the right direction.”

She said her organizati­on would like to see a reduction in recommende­d daily doses of acetaminop­hen in Canada, but she added that acetaminop­hen plays an important role in pain management and “if people perceive it as a bad drug, they may turn to other things” such as anti inflammato­ries or opioids, which also carry risks.

She said putting 500 mg tablets of acetaminop­hen behind the counter is an option that could improve safety.

Dr. David Juurlink, head of the division of clinical pharmacolo­gy and toxicology, department of medicine, at the University of Toronto, said he believes that if acetaminop­hen was brought to the market today, it would not be approved because it offers minimal pain relief, although it works reasonably well at reducing fevers, and can be toxic at levels not much higher than recommende­d doses.

There is also “emerging concern” he said about its use among pregnant women.

“The less acetaminop­hen the population uses the better, and the more a regulator helps people understand the potential harms and limited benefits, the better.”

While the focus of Delilah Saunders case last month was whether or not she would have qualified for a liver transplant because of her alcohol use, the role of acetaminop­hen in her acute illness should be getting more attention, said Yoshida.

“A death or near-death from acetaminop­hen overdose — whether intentiona­l or accidental — doesn’t make the news. From my perspectiv­e, it is very dangerous.”

It is young people, it is old people, it is everybody.

Newspapers in English

Newspapers from Canada